Preclinical research offers promise of new CDK4/6 inhibitors
Positive in vitro and in vivo antitumour effects in breast and lung cancer models and in mismatch repair-driven cancer models
Switch maintenance with darolutamide shows promise in previously treated mCRPC
Significant, but clinically modest, prolongation of radiographic progression-free survival and event-free survival was achieved with darolutamide in the SAKK 08/16 study
Does perioperative chemotherapy improve outcomes in PDAC? Evidence is not yet conclusive
Trials provide insights into perioperative and adjuvant chemotherapy for resectable pancreatic cancer
Possible changes in the standard of care for metastatic and non-metastatic prostate cancer
Addition of abiraterone acetate plus prednisone shows clear survival improvements in castration-sensitive prostate cancer
KRAS G12C inhibition shows potential for the improved management of advanced CRC
Good response rate and disease control with adagrasib and sotorasib in combination therapy shown in early-stage trials
Longer survival benefit with pembrolizumab plus chemotherapy in TNBC
Final overall survival results from the KEYNOTE-355 study confirm immune checkpoint inhibitors as the first-line treatment of choice in women with metastatic or relapsing disease
De-escalated treatment improves the management of stage IIA/B seminoma
Results from the SAKK 01/10 trial demonstrate favourable progression-free survival and low toxicity with single-dose carboplatin and involved-node radiotherapy
Liquid biopsy: novel approaches for early detection of cancer
Multi-omics approaches incorporating cell-free DNA and circulating tumour DNA show potential in early cancer detection and could help personalise treatment by tumour characteristics
Cautious optimism for new ICI-based combinations in mCRPC treatment
Early-phase studies, COSMIC-021 and CheckMate 9KD, show promising results in men with prostate cancer, but patient selection is key